Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Self-collection for high-risk HPV detection in Brazilian women using the caFeHPV (TM) test

Texto completo
Autor(es):
Lorenzi, Adriana Tarla [1] ; Fregnani, Jose Humberto T. G. [2, 3] ; Possati-Resende, Julio Cesar ; Neto, Cristovam Scapulatempo [4] ; Villa, Luisa Lina [5, 6] ; Longatto-Filho, Adhemar [2, 5, 7, 8, 9]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Barretos Canc Hosp, Ctr Mol Oncol, Barretos, SP - Brazil
[2] Barretos Canc Hosp, Ctr Researcher Support, Barretos, SP - Brazil
[3] Barretos Canc Hosp, Canc Prevent Dept, Barretos, SP - Brazil
[4] Barretos Canc Hosp, Dept Pathol, Barretos, SP - Brazil
[5] Univ Sao Paulo, Fac Med, Dept Radiol & Basic Oncol, FMUSP, BR-1246903 Sao Paulo - Brazil
[6] FCMSCSP, Santa Casa Sao Paulo Med Sch, Sao Paulo - Brazil
[7] Univ Sao Paulo, Fac Med, Lab Med Investigat LIM 14, FMUSP, BR-1246903 Sao Paulo - Brazil
[8] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst, ICVS, Braga - Portugal
[9] ICVS, 3Bs PT Govt Associate Lab, Braga - Portugal
Número total de Afiliações: 9
Tipo de documento: Artigo Científico
Fonte: GYNECOLOGIC ONCOLOGY; v. 131, n. 1, p. 131-134, OCT 2013.
Citações Web of Science: 22
Resumo

Objective. Cervical cancer is the second most common cancer among Brazilian women. High-risk human papillomavirus (hr-HPV) persistence is the primary cause of cervical neoplasia. Early detection of hr-HPV is important for identifying women at risk for developing cervical lesions. Approximately 85% of new cases of cervical cancer worldwide and 50% of the total cervical cancer deaths occurred in developing countries. Here, a new methodology to support a cervical cancer screening program was evaluated in women from various Brazilian regions. Methods. Two thousand women aged 18-77 years were enrolled in an opportunistic cervical cancer screening program and were randomized into self-vaginal or health professional-guided cervical sampling groups. The Qiagen careHPV (TM) test was performed on all samples. Pap tests were performed on all women using liquid-based cytology. Results. Positive hr-HPV results were obtained in 12.3% (245/2000) of women; similar rates were observed in self- or health professional-collected samples. Eighty-nine percent (1719/2000) of cervical cytologies classified as normal were negative to hr-HPV. Among the cytological samples, 36.6% classified as ASC-US + were positive to hr-HPV, 78.8% were LSIL and 75.0% were HSIL. Conclusions. Self-sampled and health professional-sampled vaginal/cervical specimens did not differ in their rates of detection of hr-HPV. Therefore, HPV DNA testing in self-sampled vaginal cells is an alternative to primary screening in low-resource settings. (C) 2013 Elsevier Inc. All rights reserved. (AU)

Processo FAPESP: 08/57889-1 - Instituto de Ciência e Tecnologia para o Estudo das Doenças Associadas ao Papilomavírus
Beneficiário:Luisa Lina Villa
Modalidade de apoio: Auxílio à Pesquisa - Temático